Why the study?
Does theophylline ethylenediamine improve renal water and electrolyte excretion compared to bendroflumethiazide in patients with advanced congestive heart failure on long-term bumetanide?
Does theophylline ethylenediamine improve renal water and electrolyte excretion compared to bendroflumethiazide in patients with advanced congestive heart failure on long-term bumetanide?
Theophylline ethylenediamine represents a useful alternative to thiazide diuretics for supplementary natriuretic treatment in patients with advanced congestive heart failure on long-term loop diuretics.
Answers are grounded in this paper and cite their sources.
May support theophylline ethylenediamine as thiazide alternative in advanced HF on loop diuretics; leaves open need for randomized confirmation.
The additive natriuretic and diuretic effects of theophylline ethylenediamine and of bendroflumethiazide have been compared in permutation trial tests in patients with advanced congestive heart failure receiving long-term treatment with the highly potent diuretic, bumetanide. Statistical analysis of renal water and electrolyte excretion revealed that theophylline ethylenediamine, 400 mg orally, and bendroflumethiazide, 5 mg orally, had very similar effects, both quantitatively and qualitatively. The mechanism of action of the supplementary diuretics is discussed. It is concluded that theophylline ethylenediamine represents a useful alternative to thiazide diuretics when supplementary natriuretic treatment is considered in patients with congestive heart failure during long-term treatment with potent diuretics. The significance of maintaining the potassium balance during such a combined regimen is stressed.
No takes yet. Share an insight, caveat, or question.
Sigurd et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: